8-K: UroGen Pharma Announces Positive Clinical Data and First Quarter 2024 Financial Results

UroGen Pharma reported first quarter 2024 financial results, highlighted positive clinical data for UGN-102 and JELMYTO, and provided updates on its pipeline.

Summary

• UroGen Pharma announced its first quarter 2024 financial results, with net product revenue for JELMYTO reaching $18.8 million, a 10% increase compared to the same period last year.
• The company is progressing with the New Drug Application (NDA) for UGN-102, a treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with completion expected in Q3 2024 and a potential FDA decision in early 2025.
• A post-hoc analysis of the OLYMPUS study showed that patients treated with JELMYTO for low-grade upper tract urothelial cancer (LG-UTUC) had a median duration of response of 47.8 months.
• UroGen's research and development expenses were $15.5 million for the quarter, while selling, general, and administrative expenses were $27.3 million.
• The company reported a net loss of $32.3 million, or $0.97 per share, for the first quarter of 2024.
• UroGen is reiterating its full-year 2024 net product revenue guidance for JELMYTO in the range of $95 to $102 million and operating expenses between $175 to $185 million.
• The company has $164.5 million in cash, cash equivalents, and marketable securities as of March 31, 2024.
• An IND application for UGN-103, a next-generation mitomycin-based formulation, has been accepted by the FDA, with Phase 3 studies planned for 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong clinical data and revenue growth, but the net loss and increased operating expenses temper the overall sentiment. The reiteration of revenue guidance is a positive sign.

Positives

• JELMYTO sales continue to grow, demonstrating strong market demand.
• The ENVISION study data is expected to support the NDA submission for UGN-102.
• The long-term data for JELMYTO shows promising durability of response.
• The acceptance of the IND for UGN-103 indicates progress in the pipeline.
• UroGen has a strong cash position of $164.5 million.
• The company is reiterating its revenue guidance for JELMYTO for 2024.

Negatives

• UroGen reported a net loss of $32.3 million for the first quarter of 2024.
• Operating expenses increased compared to the same period in 2023.
• Increased discounts related to Medicare refunds and 340B purchases will impact net revenues in 2024.
• The company is still reliant on JELMYTO for revenue, with UGN-102 not yet approved.

Risks

• The success of UGN-102 is dependent on positive findings from the ENVISION study and FDA approval.
• There are risks associated with the timing and success of clinical trials.
• The company faces competition in the urothelial cancer treatment market.
• UroGen's financial condition and need for additional capital in the future are potential risks.
• Unforeseen delays may impact the timing of progressing clinical trials and reporting data.

Future Outlook

UroGen expects to complete the NDA submission for UGN-102 in Q3 2024, with a potential FDA decision as early as the first quarter of 2025. The company anticipates UGN-102 will be a major growth driver and is reiterating its full-year 2024 revenue guidance for JELMYTO.

Management Comments

• Liz Barrett, President and CEO of UroGen, stated that the company has made excellent progress in both its commercial business and pipeline.
• Liz Barrett also mentioned that the upcoming announcement of 12-month duration of response results from ENVISION will be a key clinical milestone.

Industry Context

The announcement is relevant to the urothelial cancer treatment market, where there is a need for effective non-surgical options. UroGen's focus on innovative solutions aligns with the trend towards targeted therapies and improved patient outcomes in oncology.

Comparison to Industry Standards

• JELMYTO's 10% year-over-year revenue growth is a positive sign, but it is important to compare this to other companies in the oncology space, such as companies like Photocure ASA (PHTO.OL) which also focus on bladder cancer treatments.
• The median duration of response of 47.8 months for JELMYTO is a strong result, but it should be compared to other treatments for LG-UTUC, such as traditional surgery and other intravesical therapies.
• The estimated $3 billion market opportunity for UGN-102 is significant, but it is important to assess the competitive landscape and the potential for market penetration against companies like CG Oncology (CGON) who are also developing bladder cancer treatments.
• The company's R&D spending of $15.5 million is in line with other biotech companies at a similar stage of development, but it is important to monitor this spending in relation to the progress of the pipeline.

Stakeholder Impact

• Shareholders will be interested in the progress of UGN-102 and the continued growth of JELMYTO sales.
• Patients will benefit from the potential approval of new treatment options for urothelial cancers.
• Employees will be impacted by the company's financial performance and the progress of its pipeline.
• Creditors will be interested in the company's cash position and ability to meet its obligations.

Next Steps

• UroGen will complete the NDA submission for UGN-102 in Q3 2024.
• The company will present 12-month duration of response data from the ENVISION study on June 13, 2024.
• UroGen plans to initiate Phase 3 studies for UGN-103 in LG-IR-NMIBC and UGN-104 in LG-UTUC in 2024.
• The company will continue pre-launch activities for UGN-102.

Key Dates

Keywords

UroGen, JELMYTO, UGN-102, UGN-103, LG-UTUC, LG-IR-NMIBC, Mitomycin, Bladder Cancer, Urothelial Cancer, NDA, FDA, Clinical Trials, Oncology